Antithyroid drug regimen for treating Graves’ hyperthyroidism
Open accessAbstract
BACKGROUND: Antithyroid drugs are widely used in the therapy of hyperthyroidism. There are wide variations in the dose, regimen or duration of treatment used by health professionals. OBJECTIVES: To assess the effects of dose, regimen and duration of antithyroid drug therapy for Graves' hyperthyroidism. SEARCH STRATEGY: We searched seven databases and reference lists. SELECTION CRITERIA: Randomised and quasi-randomised trials of antithyroid medication for Graves' hyperthyroidism. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed risk of bias. Pooling of data for primary outcomes, and select exploratory analyses were undertaken. MAIN RESULTS: Twenty-six randomised trials involving 3388 participants were included. Overall the quality of trials, as reported, was poor. None of the studies investigated incidence of hypothyroidism, changes in weight, health-related quality of life, ophthalmopathy progression or economic outcomes. Four trials examined the effect of duration of therapy on relapse rates, and when using the titration regimen 12 months was superior to six months, but there was no benefit in extending treatment beyond 18 months. Twelve trials examined the effect of block-replace versus titration block-regimens. The relapse rates were similar in both groups at 51% in the block-replace group and 54% in the titration block-group (OR 0.86, 95% confidence interval (CI) 0.68 to1.08) though adverse effects (rashes (10% versus 6%) and withdrawing due to side effects (16% versus 9%)) were significantly higher in the block-replace group. Three studies considered the addition of thyroxine with continued low dose antithyroid therapy after initial therapy with antithyroid drugs. There was significant heterogeneity between the studies and the difference between the two groups was not significant (OR 0.58, 95% CI 0.05 to 6.21). Four studies considered the addition of thyroxine alone after initial therapy with antithyroid drugs. There was no significant difference in the relapse rates between the groups after 12 months follow-up (OR 1.15, 95% CI 0.79 to 1.67). Two studies considered the addition of immunosuppressive agents. The results which were in favour of the interventions would need to be validated in other populations. AUTHORS' CONCLUSIONS: The evidence suggests that the optimal duration of antithyroid drug therapy for the titration regimen is 12 to 18 months. The titration (low dose) regimen had fewer adverse effects than the block-replace (high dose) regimen and was no less effective. Continued thyroxine treatment following initial antithyroid therapy does not appear to provide any benefit in terms of recurrence of hyperthyroidism. Immunosuppressive therapies need further evaluation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pariani et al. reported a high requirement (64%) for long-term ATD, RAI or surgery, compared with approximately 50% in conventional Graves' disease.
“Pariani et al. [12] reported a high requirement (64%) for long-term ATD, RAI or surgery, compared with approximately 50% in conventional GD [80].”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · see citing works
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R. W., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,255 · see citing works
Cooper, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra042972 · Cited by 1,008 · see citing works
The Management of Hyperthyroidism
Wood, A. J. J., & Franklyn, J. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406163302407 · Cited by 303 · see citing works
Nakamura, H., Noh, J. Y., Itoh, K., Fukata, S., Miyauchi, A., Hamada, N., & Working Group of the Japan Thyroid Association for the Guideline of the Treatment of Graves’ Disease (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2135 · Cited by 277 · see citing works
Salvi, M., Vannucchi, G. M., Campi, I., Currò, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., et al. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02325 · Cited by 262 · see citing works
Administration of Thyroxine in Treated Graves' Disease
Hashizume, K., Ichikawa, K., Sakurai, A., Suzuki, S., Takeda, T., Kobayashi, M., Miyamoto, T., Arai, M., & Nagasawa, T. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241403 · Cited by 214 · see citing works
A systematic review of drug therapy for Graves’ hyperthyroidism
Abraham, P., Avenell, A., Park, C. M., Watson, W. A., & Bevan, J. S. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01993 · Cited by 211 · see citing works
Allannic, H., Fauchet, R., Orgiazzi, J., Orgiazzi, A., GENETET, B., LORCY, Y., GUERRIER, A. M. L., Delambre, C., & Derennes, V. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-3-675 · Cited by 192 · see citing works
REINWEIN, D., Benker, G., Lazarus, J. H., & Alexander, W. D. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501160 · Cited by 181 · see citing works
Romaldini, J. H., Bromberg, N., Werner, R. S., TANAKA, L. M., Rodrigues, H. F., WERNER, M. C., TANAKA, L. M., Rodrigues, H. F., WERNER, M. C., Farah, C. S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-3-563 · Cited by 163 · see citing works
Fassi, D. E., Nielsen, C. H., Bonnema, S. J., Hasselbalch, H. C., & Hegedűs, L. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2388 · Cited by 160 · see citing works
McIver, B., Rae, P., Beckett, G. J., Wilkinson, E., Gold, A., & Toft, A. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340403 · Cited by 135 · see citing works
Nedrebo, B., Holm, P., Uhlving, S., Sorheim, J., Skeie, S., Eide, G., Husebye, E., Lien, E., & Aanderud, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470583 · Cited by 132 · see citing works
Antithyroid drugs and Graves' disease — prospective randomized assessment of long‐term treatment
Maugendre, D., Gatel, A., Campion, L., Massart, C., Guilhem, I., LORCY, Y., Lescouarc’h, J., Herry, J. Y., & Allannic, H. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00629.x · Cited by 116 · see citing works
Glinoer, D., Nayer, P. D., & Bex, M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440475 · Cited by 111 · see citing works
Benker, G., REINWEIN, D., Kahaly, G., Tegler, L., Alexander, W. D., Faßbinder, J., & Hirche, H. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00554.x · Cited by 108 · see citing works
Rituximab in relapsing Graves' disease, a phase II study
Heemstra, K. A., Toes, R. E. M., Sepers, J. M., Pereira, A. M., Corssmit, E. P. M., Huizinga, T. W. J., Romijn, J. A., & Smit, J. W. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0084 · Cited by 105 · see citing works
Vrca, V. B., Škreb, F., Čepelak, I., Romić, Ž., & Mayer, L. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.10.028 · Cited by 98 · see citing works
Tsai, W., Pei, D., Wang, T., Wu, D., Li, J., Wei, C. L., Lee, C., Chen, S., & Kuo, S. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02249.x · Cited by 83 · see citing works
García-Mayor, R. V., Páramo, C., Cano, R. L., Méndez, L. F. P., Galofré, J. C., & Andrade, A. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03348811 · Cited by 69 · see citing works
LITHIUM CARBONATE IN THE TREATMENT OF THYROTOXICOSIS
Kristensen, O., Andersen, H. H., & Pallisgaard, G. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90414-1 · Cited by 68 · see citing works
NICHOLAS, W. C., FISCHER, R. G., STEVENSON, R. A., & BASS, J. D. (1995) · Southern Medical Journal · doi:10.1097/00007611-199509000-00018 · Cited by 64 · see citing works
Weetman, A. P., Pickerill, A. P., Watson, P. H., Chatterjee, K., & Edwards, O. M. (1994) · QJM · doi:10.1093/oxfordjournals.qjmed.a068938 · Cited by 62 · see citing works
Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism?
Lucas, A., Salinas, I., Rius, F., Pizarro, E., Granada, M., Foz, M., & Sanmartı́, A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4118 · Cited by 61 · see citing works
Prediction of Outcome in Graves' Disease after Carbimazole Treatment
Weetman, A. P., Ratanachaiyavong, S., MIDDLETON, G. W., LOVE, W., John, R. M., OWEN, G. M., Darke, C., Lazarus, J. H., HALL, R., & McGregor, A. (1986) · QJM · doi:10.1093/oxfordjournals.qjmed.a067969 · Cited by 55 · see citing works
Controversies in the management of Graves' disease
Leech, N. J., & Dayan, C. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00558.x · Cited by 55 · see citing works
Tamai, H., Hayaki, I., Kawai, K., Komaki, G., Matsubayashi, S., Kuma, K., Kumagai, L. F., & Nagataki, S. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.5.7744989 · Cited by 52 · see citing works
Cho, B. Y., Shong, M. H., Yl, K. H., Lee, H. K., Koh, C., & Mln, H. K. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02269.x · Cited by 51 · see citing works
Effect of Methimazole, with or without l -Thyroxine, on Remission Rates in Graves’ Disease1
Rittmaster, R. S., Abbott, E. C., Douglas, R., Givner, M. L., Lehmann, L., Reddy, S. S. K., Salisbury, S. R., Shlossberg, A. H., Tan, M. H., & York, S. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4613 · Cited by 50 · see citing works
Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism
Homsanit, M., Sriussadaporn, S., Vannasaeng, S., Peerapatdit, T., Nitiyanant, W., & Vichayanrat, A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01239.x · Cited by 48 · see citing works
He, C.-T., Hsieh, A.-T., Pei, D., Hung, Y.-J., Wu, L.-Y., Yang, T., Lian, W., Huang, W.-S., & Kuo, S.-W. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02032.x · Cited by 47 · see citing works
Hoermann, R., Quadbeck, B., Roggenbuck, U., Szabolcs, I., Pfeilschifter, J., Meng, W., Reschke, K., Hackenberg, K., Dettmann, J., Prehn, B., et al. (2002) · Thyroid · doi:10.1089/105072502321085225 · Cited by 43 · see citing works
Page, S. R., Sheard, C. E., Herbert, M., Hopton, M., & Jeffcoate, W. J. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00800.x · Cited by 41 · see citing works
KALLNER, G., Vitols, S., & Ljunggren, J. ‐. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.489827000.x · Cited by 38 · see citing works
Short‐term treatment of Graves' disease with methimazole in high versus low doses
Jorde, R., Ytre-Arne, K., Störmer, J., & Sundsfjord, J. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb00914.x · Cited by 35 · see citing works
Grebe, S. K. G., Feek, C. M., Ford, H. C., Fagerström, J. N., Cordwell, D. P., DeLaHunt, J., & Toomath, R. J. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00446.x · Cited by 35 · see citing works
Prospective Randomized Comparison of Propylthiouracil
Gwinup, G. (1978) · JAMA · doi:10.1001/jama.1978.03280500053019 · Cited by 34 · see citing works
Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose
Edmonds, C., & TELLEZ, M. U. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1310120 · Cited by 34 · see citing works
Treatment of hyperthyroidism with a small single daily dose of methimazole
Mashio, Y., Beniko, M., Ikota, A., Mizumoto, H., & KUNITA, H. (1988) · European Journal of Endocrinology · doi:10.1530/acta.0.1190139 · Cited by 33 · see citing works
Kubota, S., Ohye, H., Nishihara, E., Kudo, T., Ito, M., Fukata, S., Amino, N., Kuma, K., & Miyauchi, A. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.735 · Cited by 31 · see citing works
Raber, W., Kmen, E., Waldhäusl, W., & Vierhapper, H. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420117 · Cited by 31 · see citing works
Effect of Methimazole, with or without L-Thyroxine, on Remission Rates in Graves' Disease
Rittmaster, R. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.3.814 · Cited by 31 · see citing works
Escobar-Morreale, H. F., Gotarredona, J. S., Villar, L. M., García‐Robles, R., González‐Porqué, P., SANCHO, J. M., & Varela, C. (1996) · Thyroid · doi:10.1089/thy.1996.6.29 · Cited by 30 · see citing works
Pfeilschifter, J., & Ziegler, R. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1360081 · Cited by 27 · see citing works
Do higher doses of carbimazole improve remission in Graves' disease?
Wilson, R., Buchanan, L., Fraser, W. D., McKillop, J. H., & Thomson, J. A. (1996) · QJM · doi:10.1093/qjmed/89.5.381 · Cited by 21 · see citing works
Role of colestipol in the treatment of hyperthyroidism
Hagag, P., Nissenbaum, H., & Weiss, M. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03348036 · Cited by 16 · see citing works
Messina, M., Milani, P., Gentile, L., monaco, A. G. D., Brossa, C., Porta, M., & Camanni, F. (1987) · Journal of Endocrinological Investigation · doi:10.1007/bf03348132 · Cited by 16 · see citing works
TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates
Pujol, P., Osman, A., Grabar, S., Daurès, J., Galtier, F., Boegner, C., Baldet, L., Raye, R., Bringer, J., & Jaffiol, C. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00466.x · Cited by 15 · see citing works
Bromberg, N., Romaldini, J. H., Werner, R. S., Sgarbi, J. A., & WERNER, M. C. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03348703 · Cited by 13 · see citing works
Meng, W., Meng, S., Männchen, E., Hampel, R., Kirsch, G., Dannenberg, J., & Krabbe, S. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211074 · Cited by 13 · see citing works
Mastorakos, G. P., Doufas, A. G., Mantzos, E., Mantzos, J. D., & Koutras, D. A. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03348195 · Cited by 13 · see citing works
Medikamentöse Behandlung der Immunhyperthyreose (Typ Morbus Basedow)
Quadbeck, B., Hörmann, R., Janssen, O. E., & Mann, K. (2003) · Der Internist · doi:10.1007/s00108-003-0876-x · Cited by 10 · see citing works
HIGHER THAN CONVENTIONAL DOSES OF CARBIMAZOLE IN THE TREATMENT OF THYROTOXICOSIS
O'Malley, B. P., Rosenthal, F. D., Northover, B. J., Jennings, P. E., & WOODS, K. L. (1988) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1988.tb01226.x · Cited by 9 · see citing works
Chen, L., Wang, H., Gao, Y., Liang, J., Men, W., Bai, J., Qi, W.-B., Zhang, J.-S., Zhang, J., Ren, J.-Q., et al. (2008) · Current Therapeutic Research · doi:10.1016/j.curtheres.2008.08.004 · Cited by 8 · see citing works
[Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy].
Allannic, H., LORCY, Y., Am, L., Delambre, C., Stetieh, H., Am, M., & Orgiazzi, J. (1991) · PubMed · Cited by 7 · see citing works
Leclere, J.-C. (1994) · PubMed · Cited by 7 · see citing works
[Recurrence of Graves-Basedow disease: the influence of treatment schedule].
Iriarte, M. J. G., Llenas, L. F., Beroiz, A. I., Apiñániz, E. A., Erdozain, R. R., & Torre, E. L. M. (1995) · PubMed · Cited by 6 · see citing works
[Improvement of the prognosis of Basedow's disease by using high doses of carbimazole].
Duprey, J., Louis, M.-F., Ducornet, B., Lifchitz, E., Mosse, A., Sultan, M., & Izembart, M. (1988) · PubMed · Cited by 6 · see citing works
Huszno, B., Trofimiuk, M., Gołkowski, F., Plinta, T., & Szybiński, Z. (2004) · PubMed · Cited by 4 · see citing works
Thyroxine suppression therapy in Graves' disease
Toft, A. D. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80753-7 · Cited by 4 · see citing works
Soltani, A., Moayyeri, A., & Azizi, F. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.01.001 · Cited by 4 · see citing works
Antithyroid Drugs for the Treatment of Graves Disease
Peixoto, M. C., Buescu, A., alves, M. R. B. G., Albernaz, M. D. S., Coeli, C. M., & Vaisman, M. (2006) · The Endocrinologist · doi:10.1097/01.ten.0000249137.35809.b3 · Cited by 4 · see citing works
[Clinical epidemiology of Basedow's disease in Belgium].
Glinoer, D. (2000) · PubMed · Cited by 3 · see citing works
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098 · see citing works
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K. G., & Pearce, S. H. S. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 982 · see citing works
De Leo, S., Lee, S. Y., & Braverman, L. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00278-6 · Cited by 883 · see citing works
Diagnosis and management of Graves disease: a global overview
Bartalena, L. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.193 · Cited by 299 · see citing works
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00005-0 · Cited by 254 · see citing works
Quality of life in patients with benign thyroid disorders. A review
Watt, T., Grøenvold, M., Rasmussen, Å. K., Bonnema, S. J., Hegedűs, L. D., Bjørner, J. B., & Feldt‐Rasmussen, U. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02124 · Cited by 234 · see citing works
Management of Graves Thyroidal and Extrathyroidal Disease: An Update
Kahaly, G. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa646 · Cited by 231 · see citing works
A systematic review of drug therapy for Graves’ hyperthyroidism
Abraham, P., Avenell, A., Park, C. M., Watson, W. A., & Bevan, J. S. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01993 · Cited by 211 · see citing works
Kaguelidou, F., Alberti, C., Castanet, M., Guitteny, M.-A., Czernichow, P., & Léger, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0842 · Cited by 173 · see citing works
Léger, J., Gelwane, G., Kaguelidou, F., Benmerad, M., Alberti, C., & the French Childhood Graves' Disease Study Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1944 · Cited by 144 · see citing works
Antithyroid drug therapy: 70 years later
Burch, H. B., & Cooper, D. S. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0678 · Cited by 124 · see citing works
Hyperthyroidism: Diagnosis and Treatment.
Kravets, I. (2016) · PubMed · Cited by 122 · see citing works
Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis
Struja, T., Fehlberg, H., Kutz, A., Guebelin, L., Degen, C., Müeller, B., & Schüetz, P. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0725 · Cited by 122 · see citing works
Epidemiology, management and outcomes of Graves’ disease—real life data
Hussain, Y. S., Hookham, J., Allahabadia, A., & Balasubramanian, S. P. (2017) · Endocrine · doi:10.1007/s12020-017-1306-5 · Cited by 118 · see citing works
Diagnosis and management of thyrotoxicosis
Pearce, E. N. (2006) · BMJ · doi:10.1136/bmj.332.7554.1369 · Cited by 113 · see citing works
Pearce, S. H. S., Dayan, C. M., Wraith, D. C., Barrell, K., Olive, N., Jansson, L., Walker-Smith, T., Carnegie, C., Martin, K. F., Boelaert, K., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0036 · Cited by 112 · see citing works
Graves disease: latest understanding of pathogenesis and treatment options
Lanzolla, G., Marinò, M., & Menconi, F. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01016-5 · Cited by 119 · see citing works
Thyrotoxicosis: Diagnosis and Management
Sharma, A. R., & Stan, M. N. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.10.011 · Cited by 114 · see citing works
Sundaresh, V., Brito, J. P., Thapa, P., Bahn, R. S., & Stan, M. N. (2017) · Thyroid · doi:10.1089/thy.2016.0343 · Cited by 91 · see citing works
Diagnosis and management of thyrotoxicosis
Vaidya, B., & Pearce, S. H. S. (2014) · BMJ · doi:10.1136/bmj.g5128 · Cited by 90 · see citing works
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features
Pariani, N., Willis, M., Muller, I., Healy, S., Nasser, T., McGowan, A., Lyons, G., Jones, J., Chatterjee, K., Dayan, C., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00359 · Cited by 84 · see citing works
Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
Kahaly, G. J., Diana, T., Kanitz, M., Frommer, L., & Olivo, P. D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz292 · Cited by 82 · see citing works
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism
Boelaert, K., Visser, W. E., Taylor, P. N., Moran, C., Léger, J., & Persani, L. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0445 · Cited by 82 · see citing works
Muller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J., & Dayan, C. M. (2019) · European Thyroid Journal · doi:10.1159/000500881 · Cited by 78 · see citing works
Controversies in the management of Graves’ disease in children
Rivkees, S. A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0477-x · Cited by 77 · see citing works
Treatment of Graves' Hyperthyroidism: Evidence-Based and Emerging Modalities
Hegedűs, L. D. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.01.009 · Cited by 76 · see citing works
Current concepts in Graves’ disease
Girgis, C. M., Champion, B. L., & Wall, J. R. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811408488 · Cited by 73 · see citing works
Watt, T., Rasmussen, Å. K., Grøenvold, M., Bjørner, J. B., Watt, S. K., Bonnema, S. J., Hegedűs, L. D., & Feldt‐Rasmussen, U. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9364-z · Cited by 72 · see citing works
Mohlin, E., Nyström, H. F., & Eliasson, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0811 · Cited by 69 · see citing works
Approach to the Pediatric Patient with Graves' Disease: When Is Definitive Therapy Warranted?
Bauer, A. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0898 · Cited by 66 · see citing works
Struja, T., Kaeslin, M., Boesiger, F., Jutzi, R., Imahorn, N., Kutz, A., Bernasconi, L., Mundwiler, E., Müeller, B., Christ‐Crain, M., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0986 · Cited by 67 · see citing works
Calissendorff, J., & Falhammar, H. (2017) · Endocrine · doi:10.1007/s12020-017-1461-8 · Cited by 67 · see citing works
Hepatotoxicity and cutaneous reactions after antithyroid drug administration
Otsuka, F., Noh, J. Y., Chino, T., Shimizu, T., Mukasa, K., Ito, K., Ito, K., & Taniyama, M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04365.x · Cited by 63 · see citing works
Safety of long-term antithyroid drug treatment? A systematic review
Azizi, F., & Malboosbaf, R. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01054-1 · Cited by 63 · see citing works
Measuring TSH receptor antibody to influence treatment choices in Graves’ disease
Asha, H. S., & Abraham, P. (2017) · Clinical Endocrinology · doi:10.1111/cen.13327 · Cited by 61 · see citing works
Graves Disease in Children: Thyroid-Stimulating Hormone Receptor Antibodies as Remission Markers
Gastaldi, R., Poggi, E., Mussa, A., Weber, G., Vigone, M. C., Salerno, M., Delvecchio, M., Peroni, E., Pistorio, A., & Corrias, A. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.12.047 · Cited by 59 · see citing works
Léger, J., & Carel, J. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0938 · Cited by 57 · see citing works
Diagnosis and management of hyperthyroidism from prenatal life to adolescence
Léger, J., & Carel, J. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.014 · Cited by 57 · see citing works
Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016
Minamitani, K., Sato, H., Ohye, H., Harada, S., & Arisaka, O. (2017) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.26.29 · Cited by 54 · see citing works
Outcome Prediction of Treatment of Graves’ Hyperthyroidism with Antithyroid Drugs
Piantanida, E., Lai, A., Sassi, L., Gallo, D., Spreafico, E., Tanda, M. L., & Bartalena, L. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555759 · Cited by 53 · see citing works
The role of TSH receptor antibodies in the management of Graves' disease
Matthews, D. C., & Syed, A. A. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.02.006 · Cited by 52 · see citing works
The safety and efficacy of antithyroid drugs
Azizi, F. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.107 · Cited by 50 · see citing works
Carlé, A., Andersen, S. L., Boelaert, K., & Laurberg, P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0276 · Cited by 48 · see citing works
Antithyroid Drug Therapy for Graves’ Disease and Implications for Recurrence
Liu, J., Fu, J. H., Xu, Y., & Wang, G. (2017) · International Journal of Endocrinology · doi:10.1155/2017/3813540 · Cited by 48 · see citing works
Maia, A. L., Scheffel, R. S., Meyer, E. L. D. S., Mazeto, G. M. F. D. S., de Carvalho, G. A., Graf, H., Vaisman, M., Maciel, L. M. Z., Ramos, H. E., Tincani, Á. J., et al. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000300006 · Cited by 58 · see citing works
Huo, D., Cen, C., Chang, H., Ou, Q., Jiang, S., Pan, Y., Chen, K., & Zhang, J. (2021) · Communications Biology · doi:10.1038/s42003-021-02587-z · Cited by 49 · see citing works
Razvi, S., Vaidya, B., Perros, P., & Pearce, S. H. S. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02169 · Cited by 47 · see citing works
Pediatric Graves’ disease: management in the post-propylthiouracil Era
Rivkees, S. A. (2014) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2014-10 · Cited by 46 · see citing works
Radioiodine therapy versus antithyroid medications for Graves' disease
Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010094.pub2 · Cited by 48 · see citing works
Liu, X., Wong, C. K. H., Chan, W., Tang, E. H. M., Woo, Y. C., Lam, C. L. K., & Lang, B. H. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004828 · Cited by 40 · see citing works
Kawkgi, O. M. E., Ross, D. S., & Stan, M. N. (2020) · Clinical Endocrinology · doi:10.1111/cen.14374 · Cited by 42 · see citing works
The Incidence of Childhood Thyrotoxicosis Is Increasing in Both Girls and Boys in Sweden
Rodanaki, M., Lodefalk, M., Forssell, K., Arvidsson, C., Forssberg, M., & Åman, J. (2019) · Hormone Research in Paediatrics · doi:10.1159/000500265 · Cited by 36 · see citing works
The treatment of Graves' disease in children and adolescents
Lee, H. S., & Hwang, J. S. (2014) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2014.19.3.122 · Cited by 36 · see citing works
Gender Influences the Clinical Presentation and Long-Term Outcome of Graves Disease
Magri, F., Zerbini, F., Gaiti, M., Capelli, V., Ragni, A., Rotondi, M., & Chiovato, L. (2016) · Endocrine Practice · doi:10.4158/ep161350.or · Cited by 34 · see citing works
Vaidya, B., Wright, A., Shuttleworth, J., Donohoe, M. E., Warren, R. E., Brooke, A. M., Gericke, C. A., & Ukoumunne, O. C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12478 · Cited by 34 · see citing works
Park, S. Y., Kim, B. H., Kim, M., Hong, A. R., Park, J. T., Park, H., Choi, M. S., Kim, T. H., Kim, S. W., Kang, H., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02725-x · Cited by 34 · see citing works
The management and metabolic characterization: hyperthyroidism and hypothyroidism
Wang, Y., Sun, Y., Yang, B., Wang, Q., & Kuang, H. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102308 · Cited by 33 · see citing works
Struja, T., Kutz, A., Fischli, S., Meier, C., Müeller, B., Recher, M., & Schüetz, P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0939-9 · Cited by 30 · see citing works
Struja, T., Jutzi, R., Imahorn, N., Kaeslin, M., Boesiger, F., Kutz, A., Mundwiler, E., Huber, A., KRAENZLIN, M. E., Müeller, B., et al. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0363-6 · Cited by 31 · see citing works
Antithyroid Drug Treatment in Graves’ Disease
Chung, J. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1070 · Cited by 29 · see citing works
Laurberg, P., Nygaard, B., Andersen, S., Carlé, A., Karmisholt, J., Krejbjerg, A., Pedersen, I. B., & Andersen, S. L. (2014) · Journal of Thyroid Research · doi:10.1155/2014/165487 · Cited by 29 · see citing works
Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy
Stokland, A. M., Austdal, M., Nedrebø, B. G., Carlsen, S., Hetland, H. B., Breivik, L., Ueland, H. O., Watt, T., Cramon, P. K., Løvås, K., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad538 · Cited by 28 · see citing works
Azizi, F., Abdi, H., Mehran, L., & Amouzegar, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01730-1 · Cited by 29 · see citing works
Recent developments in hyperthyroidism
Kharlip, J., & Cooper, D. S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61047-3 · Cited by 27 · see citing works
Interventions for hyperthyroidism pre-pregnancy and during pregnancy
Earl, R., Crowther, C. A., & Middleton, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008633.pub3 · Cited by 27 · see citing works
Survey of Clinical Practice Patterns in the Management of 992 Hyperthyroid Patients in France
Goichot, B., Bouée, S., Castello-Bridoux, C., & Caron, P. J. (2017) · European Thyroid Journal · doi:10.1159/000453260 · Cited by 26 · see citing works
Langenstein, C., Schork, D., Badenhoop, K. W. J., & Herrmann, E. M. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9386-8 · Cited by 25 · see citing works
Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism
Abbara, A., Clarke, S. A., Brewster, R., Simonnard, A., Eng, P. C., Phylactou, M., Papadopoulou, D., Izzi‐Engbeaya, C. N., Sam, A. H., Wernig, F., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00286 · Cited by 27 · see citing works
Ali, A., Debono, M., & Balasubramanian, S. P. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05125-5 · Cited by 25 · see citing works
Song, A., Kim, S. J., Kim, M.-S., Kim, J., Kim, I.-S., Bae, G. Y., Seo, E. S., Cho, Y. S., Choi, J. Y., Cho, S. Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.687834 · Cited by 24 · see citing works
Long-term thionamide antithyroid treatment of Graves' disease
Azizi, F., Abdi, H., Amouzegar, A., & Moeini, A. S. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101631 · Cited by 24 · see citing works
Park, S., Song, E., Oh, H., Kim, M., Jeon, M. J., Kim, W. G., Kim, T. Y., Shong, Y. K., Kim, D. M., & Kim, W. B. (2019) · Endocrine · doi:10.1007/s12020-019-01987-w · Cited by 24 · see citing works
Karmisholt, J., Andersen, S. L., Pedersen, I. B., Carlé, A., Krejbjerg, A., & Nygaard, B. (2019) · Journal of Thyroid Research · doi:10.1155/2019/5945178 · Cited by 23 · see citing works
Asban, A., Chung, S., Tresler, M. A., Huilgol, P., Xie, R., Kirklin, J., Balentine, C., Lindeman, B., & Chen, H. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002922 · Cited by 14 · see citing works
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease
Azizi, F., Mehran, L., Abdi, H., & Amouzegar, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae456 · Cited by 24 · see citing works
Long-Term Treatment with Antithyroid Drugs: Efficacy and Safety
Malboosbaf, R., & Azizi, F. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.101487 · Cited by 24 · see citing works
Wood, C. L., Cole, M. F., Donaldson, M., Dunger, D. B., Wood, R., Morrison, N., Matthews, J. N. S., Pearce, S. H. S., Cheetham, T. D., & _, _. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0617 · Cited by 21 · see citing works
Zuhur, S. S., Elbüken, G., Yıldız, İ., Kadıoğlu, P., Erol, S., Şahin, S., Kılınç, F., Akbaba, G., Topçu, B., & Altuntaş, Y. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0974-3991 · Cited by 20 · see citing works
Jin, M., Jang, A., Kim, C. A., Kim, T. Y., Kim, W. B., Shong, Y. K., Jeon, M. J., & Kim, W. G. (2023) · European Thyroid Journal · doi:10.1530/etj-22-0226 · Cited by 19 · see citing works
Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease
Calissendorff, J., & Falhammar, H. (2017) · Endocrine Connections · doi:10.1530/ec-17-0025 · Cited by 19 · see citing works
Thyroid disorders in elderly: A comprehensive review
Thiruvengadam, S., & Luthra, P. (2021) · Disease-a-Month · doi:10.1016/j.disamonth.2021.101223 · Cited by 19 · see citing works
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
Song, E., Koo, M. J., Noh, E., Hwang, S. Y., Park, M., Kim, J. A., Roh, E., Choi, K. M., Baik, S. H., Cho, G. J., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1251 · Cited by 18 · see citing works
“Block-and-replace” treatment in Graves’ disease: experience in a cohort of pediatric patients
Vigone, M. C., Peroni, E., Frenna, M. D., Mora, S., Barera, G., & Weber, G. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01144-0 · Cited by 18 · see citing works
Resistant Thyrotoxicosis in a Patient with Graves Disease: A Case Report
Saleem, T., Sheikh, A., & Masood, Q. (2011) · Journal of Thyroid Research · doi:10.4061/2011/649084 · Cited by 18 · see citing works
Treatment options in the young patient with Graves' disease
Cheetham, T. D., & Bliss, R. (2015) · Clinical Endocrinology · doi:10.1111/cen.12871 · Cited by 17 · see citing works
Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
García-Mayor, R. V., & Larrañaga, A. (2010) · Medicinal Chemistry · doi:10.2174/1573406411006040239 · Cited by 18 · see citing works
Žarković, M., Wiersinga, W. M., Perros, P., Bartalena, L., Donati, S., Okosieme, O. E., Morris, D. S., Fichter, N., Lareida, J., Daumerie, C., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01320-7 · Cited by 17 · see citing works
A survey of the young person’s experience of Graves’ disease and its management
Lane, L. C., Rankin, J. M., & Cheetham, T. D. (2020) · Clinical Endocrinology · doi:10.1111/cen.14359 · Cited by 17 · see citing works
Lee, J.-E., Lee, D. H., Oh, T. J., Kim, K. M., Choi, S. H., Lim, S. K., Park, Y. J., Park, D. J., Jang, H. C., & Moon, J. H. (2018) · JMIR Research Protocols · doi:10.2196/resprot.8119 · Cited by 19 · see citing works
Kim, M., Kim, B. H., Jang, M. H., Kim, J. M., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2019) · Endocrine · doi:10.1007/s12020-019-02137-y · Cited by 17 · see citing works
Lane, L. C., Kuś, A., Bednarczuk, T., Bossowski, A. T., Daroszewski, J., Jurecka‐Lubieniecka, B., Cordell, H. J., Pearce, S. H. S., Cheetham, T. D., & Mitchell, A. L. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa347 · Cited by 16 · see citing works
Long-term management of Graves disease: a narrative review
Kim, H. (2022) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2022.00444 · Cited by 17 · see citing works
Kazakou, P., Tzanetakos, D., Vakrakou, A. G., Tzartos, J. S., Evangelopoulos, Μ.-E., Anagnostouli, M. C., Stathopoulos, P., Kassi, G., Stefanis, L., Kilidireas, C., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00981-3 · Cited by 17 · see citing works
Peng, R., Xie, P., Zhou, J., Zhou, W., Wang, Y., Chen, X., Yin, Q., Shen, L., Meng, L., Ye, L., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae892 · Cited by 15 · see citing works
Song, E., Kim, M., Park, S., Park, M., Kim, J. A., Roh, E., Yu, J. H., Kim, N. H., Seo, J. A., Kim, S. G., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.761782 · Cited by 15 · see citing works
Interventions for preventing and treating hyperthyroidism in pregnancy
Earl, R., Crowther, C. A., & Middleton, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008633.pub2 · Cited by 15 · see citing works
A Study on Nonthermal Irreversible Electroporation of the Thyroid
Lv, Y., Zhang, Y., Huang, J., Wang, Y., & Rubinsky, B. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819876307 · Cited by 14 · see citing works
Karmisholt, J., Andersen, S. L., Bulow-Pedersen, I., Krejbjerg, A., Nygaard, B., & Carlé, A. (2022) · European Thyroid Journal · doi:10.1530/etj-22-0031 · Cited by 14 · see citing works
Is beta-carotene consumption associated with thyroid hormone levels?
Far, B. F., Lomer, N. B., Gharedaghi, H., Sahrai, H., Mahmoudvand, G., & Rouzbahani, A. K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1089315 · Cited by 16 · see citing works
Hookham, J., Truran, P., Allahabadia, A., & Balasubramanian, S. P. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133756 · Cited by 13 · see citing works
- Authors
- Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F., & Bevan, J. S.
- Affiliations
- Aberdeen Royal Infirmary (GB)
- University of Aberdeen (GB)
- NHS Grampian (GB)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-01-20
- Volume
- 2010
- Issue
- 1
- Pages
- CD003420-CD003420
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC6599817
- OpenAlex
- W2167716419
- Cited by
- 249
- References
- 66
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 14 · 2023: 16 · 2022: 12 · 2021: 30 · 2020: 28 · 2019: 29 · 2018: 10 · 2017: 16 · 2016: 12 · 2015: 9 · 2014: 11 · 2013: 6 · 2012: 7
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' disease, Graves' hyperthyroidism, antithyroid drugs, treatment duration, relapse rate, immunosuppressants, adverse drug reactions, hypothyroidism, ophthalmopathy, health-related quality of life, economic outcomes
- MeSH terms
- Drug Administration Schedule, Female, Graves Disease, Humans, Hyperthyroidism, Male, Antithyroid Agents, Thyroxine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
